Cargando…

Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19

Inflammasomes are cytoplasmic multiprotein complexes formed by the host’s immune system as a response to microbial infection and cellular damage. Many studies have revealed various regulators of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome activation, while it has been rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasti, Arezina N., Synodinou, Kalliopi D., Pyrousis, Ioannis A., Nikolaki, Maroulla D., Triantafyllou, Konstantinos D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624812/
https://www.ncbi.nlm.nih.gov/pubmed/34835501
http://dx.doi.org/10.3390/microorganisms9112376
_version_ 1784606265441255424
author Kasti, Arezina N.
Synodinou, Kalliopi D.
Pyrousis, Ioannis A.
Nikolaki, Maroulla D.
Triantafyllou, Konstantinos D.
author_facet Kasti, Arezina N.
Synodinou, Kalliopi D.
Pyrousis, Ioannis A.
Nikolaki, Maroulla D.
Triantafyllou, Konstantinos D.
author_sort Kasti, Arezina N.
collection PubMed
description Inflammasomes are cytoplasmic multiprotein complexes formed by the host’s immune system as a response to microbial infection and cellular damage. Many studies have revealed various regulators of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome activation, while it has been recently shown that NLRP3 is implicated in COVID-19 pathogenesis. At the same time, probiotics counteract the inflammatory process and modulate cytokine release, thus influencing both innate and adaptive immune systems. Herein, we review the immunomodulatory potential of probiotics on the assembly of NLRP3 inflammasome, as well as the pathophysiological mechanisms supporting the use of probiotic bacteria for SARS-CoV-2 infection management, presenting evidence from preclinical studies of the last decade: in vivo, ex vivo, and mixed trials. Data show that probiotics intake is related to NLRP3 inflammasome attenuation and lower levels of inflammation markers, highlighting the beneficial effects of probiotics on inflammatory conditions. Currently, none of the ongoing clinical trials evaluating the effectiveness of probiotics intake in humans with COVID-19 has been completed. However, evidence from preclinical studies indicates that probiotics may block virus invasion and replication through their metabolites, bacteriocins, and their ability to block Angiotensin-Converting Enzyme 2 (ACE2), and by stimulating the immune response through NLRP3 inflammasome regulation. In this review, the beneficial effects of probiotics in the inflammatory process through NLRP3 inflammasome attenuation are presented. Furthermore, probiotics may target SARS-CoV-2 both by blocking virus invasion and replication and by stimulating the immune response through NLRP3 inflammasome regulation. Heterogeneity of the results—due to, among others, different bacterial strains and their metabolites, forms, dosage, and experimental designs—indicates the need for more extensive research.
format Online
Article
Text
id pubmed-8624812
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86248122021-11-27 Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19 Kasti, Arezina N. Synodinou, Kalliopi D. Pyrousis, Ioannis A. Nikolaki, Maroulla D. Triantafyllou, Konstantinos D. Microorganisms Review Inflammasomes are cytoplasmic multiprotein complexes formed by the host’s immune system as a response to microbial infection and cellular damage. Many studies have revealed various regulators of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome activation, while it has been recently shown that NLRP3 is implicated in COVID-19 pathogenesis. At the same time, probiotics counteract the inflammatory process and modulate cytokine release, thus influencing both innate and adaptive immune systems. Herein, we review the immunomodulatory potential of probiotics on the assembly of NLRP3 inflammasome, as well as the pathophysiological mechanisms supporting the use of probiotic bacteria for SARS-CoV-2 infection management, presenting evidence from preclinical studies of the last decade: in vivo, ex vivo, and mixed trials. Data show that probiotics intake is related to NLRP3 inflammasome attenuation and lower levels of inflammation markers, highlighting the beneficial effects of probiotics on inflammatory conditions. Currently, none of the ongoing clinical trials evaluating the effectiveness of probiotics intake in humans with COVID-19 has been completed. However, evidence from preclinical studies indicates that probiotics may block virus invasion and replication through their metabolites, bacteriocins, and their ability to block Angiotensin-Converting Enzyme 2 (ACE2), and by stimulating the immune response through NLRP3 inflammasome regulation. In this review, the beneficial effects of probiotics in the inflammatory process through NLRP3 inflammasome attenuation are presented. Furthermore, probiotics may target SARS-CoV-2 both by blocking virus invasion and replication and by stimulating the immune response through NLRP3 inflammasome regulation. Heterogeneity of the results—due to, among others, different bacterial strains and their metabolites, forms, dosage, and experimental designs—indicates the need for more extensive research. MDPI 2021-11-17 /pmc/articles/PMC8624812/ /pubmed/34835501 http://dx.doi.org/10.3390/microorganisms9112376 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kasti, Arezina N.
Synodinou, Kalliopi D.
Pyrousis, Ioannis A.
Nikolaki, Maroulla D.
Triantafyllou, Konstantinos D.
Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19
title Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19
title_full Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19
title_fullStr Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19
title_full_unstemmed Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19
title_short Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19
title_sort probiotics regulating inflammation via nlrp3 inflammasome modulation: a potential therapeutic approach for covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624812/
https://www.ncbi.nlm.nih.gov/pubmed/34835501
http://dx.doi.org/10.3390/microorganisms9112376
work_keys_str_mv AT kastiarezinan probioticsregulatinginflammationvianlrp3inflammasomemodulationapotentialtherapeuticapproachforcovid19
AT synodinoukalliopid probioticsregulatinginflammationvianlrp3inflammasomemodulationapotentialtherapeuticapproachforcovid19
AT pyrousisioannisa probioticsregulatinginflammationvianlrp3inflammasomemodulationapotentialtherapeuticapproachforcovid19
AT nikolakimaroullad probioticsregulatinginflammationvianlrp3inflammasomemodulationapotentialtherapeuticapproachforcovid19
AT triantafylloukonstantinosd probioticsregulatinginflammationvianlrp3inflammasomemodulationapotentialtherapeuticapproachforcovid19